Metastasis is the primary cause of
cancer-associated mortality. The ternary
IPP complex of
integrin-linked kinase, PINCH and parvin functions as a signaling platform for
integrins, which modulate numerous cellular processes including cell migration and invasion.
Chelidonine, isolated from Chelidonium majus, is a benzophenanthridine
alkaloid that exhibits anticancer properties; however, the anti-migratory and anti-invasive effects of
chelidonine remain unknown. The aim of the present study was to investigate the inhibitory effects of
chelidonine on migration and invasion of MDA-MB-231 human
breast cancer cells, and to determine the underlying mechanisms.
Chelidonine was shown to inhibit the migration and invasion of MDA-MB-231 cells in a concentration-dependent manner, without affecting the cell viability.
Chelidonine did not significantly inhibit the adhesion of the cells to
type 1 collagen (COL-I), however it did affect cell spreading and reorganization of the actin cytoskeleton.
Chelidonine also inhibited COL-I-induced
protein kinase B (Akt) activation and translocation to the plasma membrane, however, it did not significantly inhibit the activation of
focal adhesion kinase. Notably,
chelidonine treatment significantly inhibited COL-I-induced formation of the
IPP complex and activation of
IPP downstream signaling molecules, such as
extracellular signal-regulated kinase (ERK)1/2. These results suggest that
chelidonine exhibits anti-migratory and anti-invasive effects in MDA-MB-231 cells, by suppressing COL-I-induced
integrin signaling, through inhibiting the formation of the
IPP complex and subsequent down-regulation of
IPP downstream signaling molecules, such as Akt and ERK1/2. These results suggest that
chelidonine may be a potential therapeutic agent against
metastasis of invasive human
cancer cells.